As Healio previously reported, in the main results of NODE-301, etripamil (Millstone Pharmaceuticals), an L-type calcium channel blocker administered via nasal spray, missed the primary endpoint of ...

DUBLIN--(BUSINESS WIRE)--The "Paroxysmal Supraventricular Tachycardia- Pipeline Insight, 2019" drug pipelines has been added to ResearchAndMarkets.com's offering. A detailed picture of the Paroxysmal ...

CHICAGO -- The investigational L-type calcium channel blocker etripamil, formulated as a self-administered nasal spray, shortened spontaneous paroxysmal supraventricular tachycardia episodes among ...

The investigational intranasal L-type calcium channel blocker etripamil continues to be well tolerated and effective for self-treating recurrent episodes of paroxysmal supraventricular tachycardia ...

CHICAGO — A fast-acting nasal spray safely and effectively converted episodes of paroxysmal supraventricular tachycardia to normal sinus rhythm with a significant reduction in ED utilization and ...

According to DelveInsight's estimates, the paroxysmal supraventricular tachycardia market in the 7MM is expected to show positive growth, during the forecast period (2024–2034), mainly attributed to ...

A sudden, rapid heart rate will send many to the emergency room. Every year, more than 140,000 emergency room visits are related to a specific type of increased heart rate called paroxysmal ...

(MENAFN- GetNews) DelveInsight's "Paroxysmal Supraventricular Tachycardia (PSVT) Market Insights, Epidemiology, and Market Forecast 2030" report delivers an in-depth understanding of the Paroxysmal ...

According to DelveInsight's estimates, the paroxysmal supraventricular tachycardia market in the 7MM is expected to show positive growth, during the forecast period (2024-2034), mainly attributed to ...